
JULY - DECEMBER 1981

CENTERS FOR DISEASE CONTROL BIOLOGICS

SURVEILLANCE



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES . Public Health Service

COOPERATING IN THIS PROGRAM ARE THE FOLLOWING:

Armour Pharmaceutical Company Connaught Laboratories Lederle Laboratories Eli Lilly and Company Massachusetts Department of Public Health Merck Sharp & Dohme Michigan Department of Health Parke, Davis & Company Sclavo, Inc. Wyeth Laboratories

CENTERS FOR DISEASE CONTROL

IMMUNIZATION PRACTICES ADVISORY COMMITTEE

CENTER FOR PREVENTION SERVICES

IMMUNIZATION DIVISION

BIOLOGICS SURVEILLANCE

William H. Foege, M.D. Director

J. Michael Lane, M.D. Executive Secretary

J. Michael Lane, M.D. Director

Alan R. Hinman, M.D. Director

Donald L. Eddins Chief

David Sanders Statistical Assistant

FOR ADMINISTRATIVE USE ONLY

BIOLOGICS SURVEILLANCE

This summary is intended primarily for those concerned with the national use and application of immunizing agents. Although the "Net Distribution" figures are recognized as representing rough approximations only, we believe that a continuing analysis of this kind, interpreted in the light of national and local immunization surveys, will aid in assessing the overall immunization status of the population. It is anticipated that a knowledge of utilization and inventory data will assist in foreseeing possible critical shortages in vaccine supply.

Net distribution represents doses of each vaccine distributed for use during the reporting period and is depicted as gross sales or distribution less recordable returned doses. Specific data are tabulated for each antigen reported and is cumulated from the first of the year until present time. Civilian and military data have been combined.

To maintain confidentiality of an individual commercial manufacturer's report for economic and production reasons, current tabulations are available only when at least three producers market and report figures for essentially the same product. This is a basic agreement of the Biologics Surveillance program.

In some instances, where adequate time has elapsed since production and distribution, manufacturers have allowed the data to be released when not all the criteria of confidentiality could be met. Addition of these data to the summaries completes the "natural history" of early patterns of vaccine utilization.

1

PRODUCT DESCRIPTION	NET NUMBER DOSES SOLD OR DISTRIBUTED THIS QUARTER	GROSS NUMBER OF DOSES SOLD OR DISTRIBUTED THIS QUARTER	NUMBER OF DOSES RETURNED DURING QUARTER	NUMBER OF FINISHED DOSES READY FOR IMMEDIATE SHIP- MENT AT QR. END	NUMBER OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIP- MENT AT QR. END
Influenza Virus Vaccine, Trivalent	18,555,940	18,994,320	438,380	1,175,340	
Influenza Virus Vaccine, Bivalent	4 18				
Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	297,052	324,112	27,060	414,118	436,580
Diphtheria and Tetanus Toxoids with Pertussis Vaccine	5,766,045	5,837,095	71,050	3,767,050	2,549,163
Tetanus Toxoid with Diphtheria Toxoid (Adult)	2,984,375	3,026,535	42,160	2,753,025	282,211
Diphtheria Toxoid	**	**	**	**	**
Tetanus Toxoid	3,177,324	3,229,474	52,150	2,628,378	1,523,368
Pertussis Vaccine	**	**	**	**	**
Poliomyelitis Vaccine, Inactivated	5,155	5,155			· · · · · · · · · · · · · · · · · · ·
Poliomyelitis Vaccine, Live, Oral Trivalent	7,137,630	7,137,630	0	2,538,760	
Measles Virus Vaccine, Live, Attenuated*	2,301,380	2,386,072	84,692	3,054,369	
Rubella Virus Vaccine, Live*	2,172,171	2,255,622	83,451	2,739,980	
Mumps Virus Vaccine, Live*	1,619,143	1,656,295	37,152	1,673,803	
Smallpox Vaccine	778,725	805,150	26,425	208,700	22,733,425
Rabies Vaccine	**	**	**	**	**
Immune Serum Globulin, Human (reported in cc's)	594,872	609,516	14,644	130,038	1,045,572
Tetanus Immune Globulin, Human, (reported in cc's)	301,940	312,630	10,690	234,160	22,429

* All products containing this antigen ** Not shown since fewer than three distributers reported

N

QUARTERLY BIOLOGICS SUMMARY FOR OCTOBER-DECEMBER 1981

.

PRODUCT DESCRIPTION	NET NUMBER DOSES SOLD OR DISTRIBUTED THIS QUARTER	GROSS NUMBER OF DOSES SOLD OR DISTRIBUTED THIS QUARTER	NUMBER OF DOSES RETURNED DURING QUARTER	NUMBER OF FINISHED DOSES READY FOR IMMEDIATE SHIP- MENT AT QR. END	NUMBER OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIP- MENT AT QR. END
Influenza Virus Vaccine, Trivalent	618,410	1,296,510	678,100	707,060	
Influenza Virus Vaccine, Bivalent					
Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	125,030	_156,510	31,480	477,838	340,170
Diphtheria and Tetanus Toxoids with Pertussis Vaccine	4,245,975	4,327,305	81,330	3,972,305	1,385,131
Tetanus Toxoid with Diphtheria Toxoid (Adult)	2,321,860	2,353,120	31,260	1,969,671	481,585
Diphtheria Toxoid	**	**	**	**	**
Tetanus Toxoid	1,789,223	1,833,698	44,475	2,194,962	1,666,777
Pertussis Vaccine	**	**	**	**	**
Poliomyelitis Vaccine, Inactiviated	5,285	5,285			
Poliomyelitis Vaccine, Live, Oral, Trivalent	4,301,260	4,301,260		4,848,800	
Measles Virus Vaccine, Live, Attenuated*	1,131,266	1,206,373	75,107	3,100,560	
Rubella Virus Vaccine, Live*	1,088,580	1,183,896	95,316	2,736,806	
Mumps Virus Vaccine, Live*	844,966	875,075	30,109	1,835,956	
Smallpox Vaccine	657,275	677,675	20,400	98,650	22,470,225
Rabies Vaccine	**	**	**	**	**
Immune Serum Globulin, Human (reported in cc's)	488,204	501,544	13,340	783,728	222,426
Tetanus Immune Globulin, Human (reported in cc's)	175,850	185,330	9,480	92,960	56,940

* All products containing this antigen.

** Not shown since fewer than three distributers reported.

 $\boldsymbol{\omega}$

TOTAL NET DOSES DISTRIBUTED UNITED STATES, 1977-1981

BIOLOGICS	1977	1978	1979	1980	1981
Influenza Virus Vaccine, Trivalent	21,749,587	19,892,960	18,270,794	12,415,890	19,829,170
Influenza Virus Vaccine, Monovalent	5,199,485	518,020	- 99,510	1.121.121	
Influenza Virus Vaccine, Bivalent	11.085 1.50	1919-67		- 25,270	- 530
Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	904,966	823,326	884,165	751,280	789,712
Diphtheria and Tetanus Toxoids with Pertussis Vaccine	16,862,740	17,992,360	18,414,768	21,815,510	18,827,085
Tetanus Toxoid with Diphtheria Toxoid (Adult)	9,650,244	9,191,122	9,463,907	10,310,850	10,263,995
Diphtheria Toxoid	3,590	960	1,933	**	**
Tetanus Toxoid	12,942,190	10,971,238	12,508,262	11,696,607	9,988,452
Pertussis Vaccine	21,110	100,610	86,680	**	**
Poliomyelitis Vaccine, Inactivated	**	**	40,465	28,665	20,370
Poliomyelitis Vaccine, Live, Oral, Trivalent	23,211,560	24,579,120	24,538,960	23,746,180	22,785,255
Measles Virus Vaccine, Live, Attenuated*	10,675,623	8,931,344	8,520,168	7,957,863	6,624,995
Rubella Virus Vaccine, Live*	7,698,639	7,552,861	8,188,070	7,235,614	6,234,065
Mumps Virus Vaccine, Live*	4,092,773	4,648,810	5,285,014	5,207,951	4,780,797
Smallpox Vaccine	4,493,239	4,284,029	3,611,147	2,829,162	2,422,400
Rabies Vaccine	**	**	**	**	**
Immune Serum Globulin, Human (reported in cc's)	4,905,267	4,005,759	3,887,745	2,954,226	2,305,895
Tetanus Immune Globulin, Human (reported in cc's)	1,320,590	1,339,681	1,360,051	858,546	894,290

presented generation in the second states the

* All products containing this antigen ** Not shown since fewer than three distributers reported